The use of highly active antiretroviral therapy in the treatment of HIV infection has resulted in significant reductions in mortality and morbidity worldwide. However, there is considerable interindividual variability in patient outcomes in terms of drug disposition, drug efficacy and adverse events. The basis of these differences is multifactorial, but host genetics are believed to play a significant part. To date, most attempts to explain this variability have focused on isolated single nucleotide polymorphisms. The most exciting development to date is the discovery of human leukocyte antigen subtype B*5701 (HLA B*5701) as a strong predictor of the abacavir hypersensitivity reaction. There is a gradual move away from single candidate gene analyses towards a high throughput whole genome approach. These studies must be performed on well characterized cohorts and reported associations must be validated in independent, ethnically diverse populations.
MahunguTW, RodgerAJ, JohnsonMA. HIV as a chronic disease. Clin Med2009, in press
2.
KalowW, TangBK, EndrenyiL. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics1998;8:283–9
DeeksSG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis2000;30:S177–S184
5.
HoeheMR, TimmermannB, LehrachH. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol2003;4:351–78
6.
O'shaughnessyKM. HapMap, pharmacogenomics, and the goal of personalized prescribing. Br J Clin Pharmacol2006;61:783–6
7.
A haplotype map of the human genome. Nature2005;437:1299–320
8.
AndersonPL, KakudaTN, LichtensteinKA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis2004;38:743–53
9.
VealGJ, BackDJ. Metabolism of zidovudine. Gen Pharmacol1995;26:1469–75
10.
SchuetzJD, ConnellyMC, SunD, MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med1999;5:1048–51
11.
TakenakaK, MorganJA, SchefferGL, Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res2007;67:6965–72
12.
AndersonPL, LambaJ, AquilanteCL, SchuetzE, FletcherCV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr2006;42:441–9
13.
FletcherCV, KawleSP, KakudaTN, Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS2000;14:2137–44
14.
WangX, FurukawaT, NitandaT, Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol2003;63:65–72
15.
MallalS, NolanD, WittC, Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet2002;359:727–32
16.
MallalS, PhillipsE, CarosiG, HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med2008;358:568–79
17.
HughesAR, MostellerM, BansalAT, Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics2004;5:203–11
18.
CutrellAG, HernandezJE, FlemingJW, Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother2004;38:2171–2
19.
SaagM, BaluR, PhillipsE, High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis2008;46:1111–8
20.
WatersLJ, MandaliaS, GazzardB, NelsonM. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS2007;21:2533–4
21.
UwaiY, IdaH, TsujiY, KatsuraT, InuiK. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res2007;24:811–5
22.
MallantsR, VanOK, VanVL, Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica2005;35:1055–66
23.
RayAS, CihlarT, RobinsonKL, Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother2006;50:3297–304
24.
WinstonA, AminJ, MallonP, Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med2006;7:105–11
25.
MalikA, AbrahamP, MalikN. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment – case report and review of literature. J Infect2005;51:E61–E65
26.
VerhelstD, MongeM, MeynardJL, Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis2002;40:1331–3
27.
IzzedineH, HulotJS, VillardE, Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis2006;194:1481–91
28.
SetzerB, SchlesierM, ThomasAK, WalkerUA. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes. Antivir Ther2005;10:327–34
29.
BrinkmanK, SmeitinkJA, RomijnJA, ReissP. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet1999;354:1112–5
30.
HulganT, HaasDW, HainesJL, Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS2005;19:1341–9
31.
BastardJP, CaronM, VidalH, Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet2002;359:1026–31
32.
NolanD, MooreC, CastleyA, Tumour necrosis factor-alpha gene −238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS2003;17:121–3
33.
MaherB, AlfirevicA, VilarFJ, TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS2002;16:2013–8
34.
TarrPE, TaffeP, BleiberG, Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis2005;191:1419–26
35.
WardBA, GorskiJC, JonesDR, The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther2003;306:287–300
36.
EricksonDA, MatherG, TragerWF, LevyRH, KeirnsJJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos1999;27:1488–95
37.
RiskaP, LamsonM, MacGregorT, Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos1999;27:895–901
38.
LangT, KleinK, FischerJ, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics2001;11:399–415
39.
DestaZ, SausseleT, WardB, Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics2007;8:547–58
40.
HaasDW, RibaudoHJ, KimRB, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS2004;18:2391–400
41.
TsuchiyaK, GatanagaH, TachikawaN, Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun2004;319:1322–6
42.
RotgerM, ColomboS, FurrerH, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics2005;15:1–5
43.
Rodriguez-NovoaS, BarreiroP, RendonA, Influence of 516G>T polymorphisms at the gene encoding the CYP450–2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis2005;40:1358–61
44.
MehlotraRK, BockarieMJ, ZimmermanPA. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol2007;64:391–5
45.
SaitohA, SarlesE, CapparelliE, CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS2007;21:2191–9
46.
PenzakSR, KabuyeG, MugyenyiP, Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med2007;8:86–91
47.
WyenC, HendraH, VogelM, Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother2008;61:914–8
48.
LiAP, KaminskiDL, RasmussenA. Substrates of human hepatic cytochrome P450 3A4. Toxicology1995;104:1–8
49.
HeP, CourtMH, GreenblattDJ, von MoltkeLL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther2005;77:373–87
50.
Zeigler-JohnsonC, FriebelT, WalkerAH, CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res2004;64:8461–7
51.
di LulioJ, RotgerM, LubomirovR, Genetic variation in accessory metabolic pathways is associated with extreme efavirenz exposure in individuals with impaired CYP2B6 function. 15th Conference on Retroviruses and Opportunistic Infections2008; Session 38 (Oral Abstract 133)
52.
MarzoliniC, TelentiA, DecosterdLA, Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS2001;15:71–5
53.
CsajkaC, MarzoliniC, FattingerK, Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther2003;73:20–30
54.
Gonzalez deRD, BonoraS, GarazzinoS, Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother2005;49:3966–9
55.
VeldkampAI, WeverlingGJ, LangeJM, High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS2001;15:1089–95
56.
de Vries-SluijsTE, DielemanJP, ArtsD, Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet2003;42:599–605
HaasDW, SmeatonLM, ShaferRW, Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis2005;192:1931–42
59.
KimRB, FrommMF, WandelC, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest1998;101:289–94
60.
MarzoliniC, PausE, BuclinT, KimRB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther2004;75:13–33
61.
StormerE, von MoltkeLL, PerloffMD, GreenblattDJ. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res2002;19:1038–45
62.
AlmondLM, EdirisingheD, DaltonM, Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther2005;78:132–42
63.
FellayJ, MarzoliniC, MeadenER, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet2002;359:30–6
64.
GazzardBG. Efavirenz in the management of HIV infection. Int J Clin Pract1999;53:60–4
65.
LochetP, PeyriereH, LottheA, Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med2003;4:62–6
66.
ShahMD, BaldersonK. A manic episode associated with efavirenz therapy for HIV infection. AIDS2003;17:1713–4
PeyriereH, MauboussinJM, RouanetI, Management of sudden psychiatric disorders related to efavirenz. AIDS2001;15:1323–4
69.
NunezM, Gonzalez deRD, GallegoL, Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr2001;28:399–400
70.
KappelhoffBS, vanLF, RobinsonPA, Are adverse events of nevirapine and efavirenz related to plasma concentrations?Antivir Ther2005;10:489–98
71.
GallegoL, BarreiroP, delRR, Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis2004;38:430–2
72.
GatanagaH, HayashidaT, TsuchiyaK, Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis2007;45:1230–7
73.
RotgerM, TelentiA. Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?Eur J Clin Pharmacol2008;64:335–6
74.
TornoMS, WittMD, SaitohA, FletcherCV. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. Pharmacotherapy2008;28:782–7
75.
SternJO, RobinsonPA, LoveJ, A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr2003;34:S21–S33
76.
DieterichDT, RobinsonPA, LoveJ, SternJO. Drug-induced liver injury associated with the use of non-nucleoside reverse-transcriptase inhibitors. Clin Infect Dis2004;38:S80–S89
77.
AdkinsJC, NobleS, Efavirenz. Drugs1998;56:1055–64
78.
de MaatMM, terHR, MulderJW, Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol2003;59:457–62
79.
de MaatMM, MathotRA, VeldkampAI, Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals. Pharmacol Res2002;46:295–300
80.
MartinAM, NolanD, JamesI, Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS2005;19:97–9
81.
ShentonJM, TeranishiM, bu-AsabMS, YagerJA, UetrechtJP. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem Res Toxicol2003;16:1078–89
82.
VitezicaZG, MilpiedB, LonjouC, HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS2008;22:540–1
83.
GatanagaH, YazakiH, TanumaJ, HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS2007;21:264–5
84.
LitteraR, CarcassiC, MasalaA, HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS2006;20:1621–6
85.
RitchieMD, HaasDW, MotsingerAA, Drug transporter and metabolizing enzyme gene variants and non-nucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis2006;43:779–82
86.
HaasDW, BartlettJA, AndersenJW, Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis2006;43:783–6
87.
SquiresK, LazzarinA, GatellJM, Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr2004;36:1011–9
88.
onso-VillaverdeC, CollB, GomezF, The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS2005;19:341–2
89.
ErnestCS, HallSD, JonesDR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther2005;312:583–91
90.
CooperCL, van HeeswijkRP, GallicanoK, CameronDW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis2003;36:1585–92
91.
BoffitoM, BackDJ, BlaschkeTF, Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses2003;19:825–35
92.
FrohlichM, HoffmannMM, BurhenneJ, Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol2004;58:443–4
93.
MoulySJ, MathenyC, PaineMF, Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther2005;78:605–18
94.
JosephsonF, AllqvistA, JanabiM, CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther2007;81:708–12
95.
ZhangKE, WuE, PatickAK, Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother2001;45:1086–93
96.
KhaliqY, GallicanoK, SeguinI, Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol2000;50:108–15
97.
BurgerDM, SchwietertHR, ColbersEP, BeckerM. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir. Br J Clin Pharmacol2006;62:250–2
98.
SaitohA, SinghKK, PowellCA, An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS2005;19:371–80
99.
ThiebautF, TsuruoT, HamadaH, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA1987;84:7735–8
100.
Cordon-CardoC, O'BrienJP, CasalsD, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA1989;86:695–8
101.
KlimeckiWT, FutscherBW, GroganTM, DaltonWS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood1994;83:2451–8
102.
Kimchi-SarfatyC, OhJM, KimIW, A ‘silent’ polymorphism in the MDR1 gene changes substrate specificity. Science2007;315:525–8
103.
RodriguezNS, BarreiroP, RendonA, Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C–>T polymorphism at the multidrug resistance gene 1. Clin Infect Dis2006;42:291–5
104.
Rodriguez-NovoaS, Martin-CarboneroL, BarreiroP, Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS2007;21:41–6
105.
MaQ, BrazeauD, ZingmanBS, Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics2007;8:227–35
106.
ColomboS, BuclinT, DecosterdLA, Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther2006;80:307–18
107.
BurgerDM, HoetelmansRM, HugenPW, Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther1998;3:215–20
108.
HaasDW, WuH, LiH, MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr2003;34:295–8
109.
NasiM, BorghiV, PintiM, MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS2003;17:1696–8
110.
VerstuyftC, MarcellinF, Morand-JoubertL, Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS2005;19:2127–31
111.
CarrA, SamarasK, BurtonS, A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS1998;12:F51–F58
112.
MahleyRW, RallSCJr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet2000;1:507–37
113.
ArnedoM, TaffeP, SahliR, Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics2007;17:755–64
114.
MonaghanG, RyanM, SeddonR, HumeR, BurchellB. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet1996;347:578–81
RotgerM, TaffeP, BleiberG, Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis2005;192:1381–6
117.
MacArthurRD, NovakRM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis2008;47:236–41
118.
KassahunK, McIntoshI, CuiD, Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos2007;35:1657–63
